Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-16
2007-10-16
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S126000
Reexamination Certificate
active
11366866
ABSTRACT:
Compounds of formula I are disclosed:in which X is a 5-membered heteroaryl ring and R is as defined herein. The compounds are inhibitors of the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.
REFERENCES:
patent: 3406184 (1968-10-01), Raasch
patent: 3715362 (1973-02-01), Dominianni
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 2004/0029862 (2004-02-01), Belanger et al.
patent: 2004/0049038 (2004-03-01), Collins et al.
patent: 2005/0182111 (2005-08-01), Pineiro et al.
patent: 2005/0215602 (2005-09-01), Campbell et al.
patent: WO98/38156 (1998-09-01), None
patent: WO 01/70677 (2001-09-01), None
patent: WO 02/36555 (2002-05-01), None
patent: WO 03/093251 (2003-11-01), None
patent: WO 03/093253 (2003-11-01), None
J. E. Franz, et al.: Journal of Organic Chemistry, vol. 29, No. 10, Oct. 1964, pp. 2922-2927.
R. Huisgen, et al.: Chemische Berichte, vol. 98, No. 12, Dec. 1965, pp. 3992-4013.
S. Itsuno, et al.: Journal of the Chemical Society, Perkin Transactions 1, No. 10, Jul. 15, 1999, pp. 2011-2016.
M. Narisada, et al.: Journal of Medicinal Chemistry, vol. 31, No. 9, Sep. 1988, pp. 1847-1854.
K. B. Sharpless, et al.: Journal of Organic Chemistry, vol. 41, No. 1, Jan. 9, 1976, pp. 176-177.
Y. Yamaguchi, et al.: Xenobiotica, vol. 26, No. 6, Jun. 1996, pp. 613-626.
L. H. Zalkow, et al.: Journal of the American Chemical Society, vo. 86, No. 19, pp. 4208-4209, Oct. 5, 1964.
L. H. Zalkow, et al.: Journal of Organic Chemistry, vol. 28, No. 12, Dec. 1963, pp. 3303-3309.
J. L. Castro et al., “Synthesis and Biological Activity of . . . ,” J. Med. Chem., vol. 37(19), pp. 3023-3032, (1994).
P. Aeberli et al., “Neuropharmacological Investigation of N-Benzylsulfamides,” J. Med. Chem., vol. 10(4), pp. 636-642, (1967).
A. C. Oehlshlager et al., “Bridged Ring Compounds . . . ,” J. Med. Chem., vol. 31, pp. 1682-1688, (1965).
G. M. Rishton et al., “Fenchylamine Sulfonamide Inhibitors of Amyloid Beta Peptide Production by the Gamma-Secretase Proteolytic Pathway . . . ”, J. Med. Chem, vol. 43, pp. 2297-2299 (2000).
Collins Ian James
Cooper Laura Catherine
Harrison Timothy
Keown Linda Elizabeth
Madin Andrew
Krovatin William
Merck Sharp & Dohme Limited
Saeed Kamal A.
Todaro John C.
LandOfFree
Heteroaryl substituted spirocyclic sulfamides for inhibition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl substituted spirocyclic sulfamides for inhibition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted spirocyclic sulfamides for inhibition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3900506